



## **Swiss Summary of the risk management plan (RMP)**

**For**

**Oxervate**  
**(Cenegermin)**

Version 2.0  
(September 2021)

Dompé International S.A  
Rue de la Fontaine 3  
c/o Fiduciaire Guy Borloz S.A.  
Aigle 1860, Switzerland

## **Disclaimer**

The Risk Management Plan (RMP) is a comprehensive document submitted as part of the application dossier for market approval of a medicine. The RMP summary contains information on the medicine's safety profile and explains the measures that are taken in order to further investigate and follow the risks as well as to prevent or minimize them. The RMP summary of Oxervate is a concise document and does not claim to be exhaustive. As the RMP is an international document, the summary might differ from the "Arzneimittelinformation / Information sur le médicament" approved and published in Switzerland, e.g. by mentioning risks occurring in populations or indications not included in the Swiss authorization. Please note that the reference document which is valid and relevant for the effective and safe use of Oxervate in Switzerland is the "Arzneimittelinformation/ Information sur le médicament" (see [www.swissmedic.ch](http://www.swissmedic.ch)) approved and authorized by Swissmedic. Dompé International SA is fully responsible for the accuracy and correctness of the content of the published summary RMP of Oxervate.

## Summary of risk management plan for Oxervate (Cenegermin)

This is a summary of the risk management plan (RMP) for Oxervate. The RMP details important risks of Oxervate, how these risks can be minimised, and how more information will be obtained about Oxervate's risks and uncertainties (missing information).

Oxervate's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Oxervate should be used.

This summary of the RMP for Oxervate should be read in the context of all this information including the assessment report of the evaluation and its plain-language summary, all which is part of the European Public Assessment Report (EPAR).

Important new concerns or changes to the current ones will be included in updates of Oxervate's RMP.

### I. The medicine and what it is used for

Oxervate is authorised for treatment of moderate (persistent epithelial defect) or severe (corneal ulcer) Neurotrophic Keratitis in adults (see SmPC for the full indication). It contains Recombinant human nerve growth factor (rhNGF) as the active substance and it is given by Eye drops, solution.

Further information about the evaluation of Oxervate's benefits can be found in Oxervate's EPAR, including in its plain-language summary, available on the EMA website, under the medicine's webpage <https://www.ema.europa.eu/en/medicines/human/EPAR/oxervate>.

### II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of Oxervate, together with measures to minimise such risks and the proposed studies for learning more about Oxervate's risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute *routine risk minimisation* measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed, including Periodic Safety Update Report (PSUR) assessment, so that immediate action can be taken as necessary. These measures constitute *routine pharmacovigilance activities*.

## ***II.A List of important risks and missing information***

Important risks of Oxervate are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely taken. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Oxervate. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine);

<b>List of important risks and missing information</b>	
Important identified risks	None
Important potential risks	None
Missing information	None

## ***II.B Summary of important risks***

Not applicable

## ***II.C Post-authorisation development plan***

Not applicable

### **II.C.1 Studies which are conditions of the marketing authorisation**

There are no studies which are conditions of the marketing authorisation or specific obligation of Oxervate.

### **II.C.2 Other studies in post-authorisation development plan**

There are no studies required for Oxervate.